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In global health research, short-term, small-scale clinical trials with fixed, two-arm trial designs that generally do
not allow for major changes throughout the trial are the most common study design. Building on the introductory
paper of this Series, this paper discusses data-driven approaches to clinical trial research across several adaptive
trial designs, as well as the master protocol framework that can help to harmonise clinical trial research efforts in
global health research. We provide a general framework for more efficient trial research, and we discuss the
importance of considering different study designs in the planning stage with statistical simulations. We conclude
this second Series paper by discussing the methodological and operational complexity of adaptive trial designs
and master protocols and the current funding challenges that could limit uptake of these approaches in global
health research.

Introduction
Randomised clinical trials are an underused tool in global
health research that have the potential to drive evidenceinformed policy making in low-income and middleincome countries (LMICs). Panel 1 shows the findings of
systematic searches of trials from two key areas of global
health: maternal, newborn, and child health, and malaria.
Most global health trials have a simple fixed design that
uses two arms, is typically small in sample size (less than
100 patients), and is underpowered. Although many trials
have been under
taken in these research areas, the
information derived from these trials is inconsistent and
might suggest the need for both better trial planning and
coordination.
Newer approaches for the planning and implementation
of trials than these fixed, two-arm designs are currently
being used by specialised trialist groups that are
largely based in (and working in) the USA and
the UK. Alternative design choices include data-driven
approaches in clinical trial research that are known as
adaptive trial designs. An adaptive trial design is a type of
trial design that allows for prespecified adaptations
throughout the trial, in which the decision to adapt is
dependent on the interim data collected.5,6 Particularly
when epidemiology is poorly understood and sample
size calculations are challenging, this type of trial can
minimise the limitations conferred by fixed trial designs
by planning for possible changes and methods of
evaluating interim data through extensive simulations.7,8
Because there are many unknowns and difficulties in
trial planning in LMICs, simulations can be a powerful
tool that can enable more efficient and ethical clinical
trial research for global health research.9 Simulations can
help to avoid trial design decisions that trial investigators
might later regret, after the trial shows negative findings
(areas of anticipated regret).7 Whether the design is
adaptive or not, simulations can be used for any designs
and any clinical areas of research, but they are not often
used in the context of global health.9
www.thelancet.com/lancetgh Vol 9 May 2021

Adopting the framework of master protocols (which
have also been referred to as core protocols) might help to
minimise the fragmented nature of research efforts within
the global health trial landscape. The term master protocol
generally refers to a single overarching protocol that has
been developed to evaluate multiple interventions, with a
general goal of improving efficiency and standardisation
in clinical research.10–14 Compared with conventional
clinical trials, master protocols are planned to be larger in
scale and offer flexibility and sustainability in answering
multiple research questions over longer periods of time
under a single protocol.14,15 A landscape analysis of master
Key messages
• An adaptive trial design is a validated method that has
been used extensively but, in the past 30 years, this
approach has predominantly been used for pharmaceutical
therapeutic research under regulatory scrutiny in highincome countries. Consideration of data-driven
approaches might become increasingly important for
global health trial investigators working in low-income
and middle-income countries.
• No trial designs should be used by default. Instead, trial
planning practices should include considerations of
multiple designs and the possibility of using statistical
simulations to inform efficient trial designs for the given
clinical question in conjunction with other factors.
• The principles of master protocols and their subtypes in
basket, umbrella, and platform trials can be tailored and
adapted to suit the needs of a multitude of health
problems. Such study designs might not only improve the
quality and standardisation of trial research but could also
help in reinforcing local infrastructure and improving
training and professional development opportunities,
particularly in low-income and middle-income countries,
given that master protocol studies are generally planned to
be large in scale and long term.
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protocols by use of a systematic literature review has
shown a rapid increase in the use of these designs, but
their application has largely been limited to research being
done in high-income country (HIC) settings.15
This Series paper builds on the discussion from the first
paper9 of this Series. We first introduce the concepts of
adaptive trial designs and master protocols, and we
present specific study designs that can be applied in global
health research. We discuss how the master protocol
framework can be used to promote sustainability and
holistically improve trial research in LMICs. We outline a
general framework for improved trial planning and future
considerations that both researchers and funding bodies
can make to improve global health research.

Adaptive trial designs for global health
Overview of adaptive trial designs

See Online for appendix

In global health research, there are often many instances
of substantial uncertainty regarding the natural history
of the diseases and how best to intervene. As a result,
assumptions with a high degree of uncertainty might be
required, which can often be challenging to plan and
design trials. Therefore, it is important to use clinical

Panel 1: Assessment of individually randomised global health clinical trials carried
out in low-income and middle-income countries (LMICs)
Methods
To assess design characteristics of individually randomised clinical trials that are carried out
in LMICs, we focused on two key research areas within global health: maternal, newborn,
and child health (MNCH), and malaria. For MNCH, we included LMIC-based individual
randomised clinical trials that investigated interventions under the domains of
micronutrients, balanced energy protein or food supplements, deworming, maternal
education for adverse birth and linear growth outcomes during pregnancy, exclusive
breastfeeding, and complementary feeding periods (ie, first 1000 days of life). For malaria,
we included intermittent preventive therapies in the form of antimalarial drugs for
pregnant women, infants, and children residing in LMICs. These trials have been identified
from systematic reviews that have been published between 2017 and 2019.1–4 A total of
190 LMIC-based trials published in these two research areas (158 MNCH trials
and 32 malaria trials) were included for this assessment. The list of included trials is
provided in the appendix (pp 6–14).
Number of interventions, sample size, and trial duration
The modal (ie, most frequent) number of interventions investigated in these global health
trials is two (IQR 2–3), meaning two-arm trials were most often undertaken. The median
sample size was 441 (IQR 204–1134). The median trial duration was 22·0 months
(13·0–37·0).
Trial planning practices
132 trials studied a continuous outcome as the primary outcome and 58 trials studied a
binary outcome as the primary outcome. 41 (22%) of the 190 trials did not report any details
on their sample size justification (38 MNCH trials and three malaria trials). Only 65 (34%) of
190 trials in these key areas within global health adequately reported their sample size
calculation. For instance, of the 132 trials with a continuous primary outcome, 43 (33%)
reported on the assumed effect size and expected dispersion (eg, standard deviation) of the
primary outcome. Among assessable trials that studied binary outcomes, only 22 (38%) of
58 trials reported on their assumed treatment effect size and baseline control event rates.
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trial simulations to explore a multitude of scenarios to
guide the selection of trial design parameters while
considering different trial designs, to determine the
optimal design for a given research question.
The default use of fixed trial designs can pose
considerable inefficiencies that cannot easily be afforded
in the context of constrained funding, as often applies to
global health research. In clinical trials with fixed trial
designs, the data are not typically evaluated until the last
participant has finished their follow-up. Adaptive trial
designs allow for more frequent learning by implementing
preplanned interim evaluations that use prespecified
decision rules.8,16 The ongoing learning nature of adaptive
trial designs can test for the adequacy of the assumptions
that the investigators have made going into the trial
early, such that modifications to the trial designs can
be made, to increase the likelihood of detecting a truepositive effect or stopping the trial early if the intervention
is shown to be futile.
Although there might be potential concerns for
investigator bias, adaptive trial designs are protocoldriven.8,16 The specific design components are not
modified by the trial investigators.17 There are explicit
plans for interim evaluations, potential adaptations, and
decision rules that are written into the trial protocol
before any participants are recruited into the trial.8,16
If any of the predetermined decision rules are met during
an interim analysis, adaptations are made as planned, to
avoid undermining the trial’s validity and integrity.18
Interim analyses are often done by independent statis
ticians and reviewed by an independent data monitoring
committee.18–21 Data monitoring committees are often
staffed by scientists and statisticians from HICs, but it
is important for clinical trials set in LMICs to have
representation of data monitoring committee members
from the LMICs.

Sample size re-estimation
Sample size calculation is an important part of trial
planning. Typically, little information is available
with regard to baseline disease prevalence, anticipated
dropout, loss to follow-up and other features essential
for sample size calculations. As such, determining
sample size calculations can be a difficult task; trial
investigators in global health research undertake sample
size calculations with assumptions that are justified with
the use of a mixture of subjectivity, external studies with
limited generalisability to the setting of interest, or smallscale pilot studies or proof-of-concept studies with high
degrees of uncertainty. Sample size re-estimation can be
a valuable tool for increasing the probability of detecting
treatment effects. Sample size re-estimation is a type of
adaptive trial design that allows for modification of the
sample size target based on interim data.22 If the event
rate is shown to be lower than foreseen at the interim
analysis, the trial’s statistical power will consequently
be lower than originally planned. Adaptive trials with
www.thelancet.com/lancetgh Vol 9 May 2021
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planned sample size re-estimation would allow for the
target sample size to be increased to improve the trial’s
statistical power.

Seamless designs
For drug development, clinical trial investigations are
usually done in phases, with earlier phases undertaken
with exploratory purposes (eg, testing of dose ranges),
followed by a confirmatory phase 3 trial that can provide
strong evidence of drug efficacy or safety, or both.23 With
conventional approaches to clinical trial evaluation, the
knowledge from each phase can only be used after the
trial is finished.16 Even if an early exploratory clinical trial
is undertaken and shows results that are promising
enough to justify a further confirmatory trial, clinical
evaluation of such an intervention would be paused
between the two clinical trials. However, a seamless
design is a type of trial design that allows for a trial in
the non-confirmatory stages to immediately continue
onto the subsequent trial.16,24 The most commonly used
seamless designs are seamless phase 2 to phase 3 trials,
because phase 2 and phase 3 can have considerable
overlaps in essential components (eg, clinical settings).24
Seamless designs can be useful for global health
research. For vaccine development, as one example, the
efficiency of trial investigation of candidate vaccines
can be improved by use of the seamless phase 2 to
phase 3 approach that has been used for a clinical
evaluation of the 9-valent human papillomavirus vaccine
by Joura and colleagues.25 Before this adaptive trial with a
seamless design was undertaken, there was uncertainty
about an optimal dose of the 9-valent human papilloma
virus vaccine; therefore, this seamless trial began with a
phase 2 stage that assessed three dosages (low, medium,
and high) and immunological endpoints were used to
select the optimal dosage for the subsequent phase 3
stage.25 The medium-dose vaccine, which showed
adequate immunogenicity and safety profiles, was then
seamlessly transitioned into a phase 3 trial, in which it
was tested and confirmed for non-inferiority against the
standard-of-care vaccine (4-valent human papillomavirus
vaccine). The seamless design substantially shortened
the amount of time to complete a conclusive phase 3
trial, given that there was no pause between phase 2 and
phase 3.25,26
The nomenclature of different clinical trial phases
developed under the drug development framework
might not apply to all global health research. However,
similar to early stage clinical trials for drug develop
ment, early stage exploratory trials evaluating nonpharmaceutical inter
ventions in global health should
be more concerned with false-negative discoveries.
Because confirmatory trials require more resources
than exploratory trials, undertaking exploratory trials
before committing resources for confirmatory trials
is important. Instead of undertaking exploratory and
confirmatory trials separately, adopting seamless designs
www.thelancet.com/lancetgh Vol 9 May 2021

in which the exploratory stage can seamlessly continue
onto the confirmatory stage (when positive findings are
shown from the exploratory stage) could expedite clinical
evaluations in global health research.

Response-adaptive randomisation (RAR)
RAR is a type of adaptive trial design in which allocation
ratios can be adapted on the basis of interim analyses
over the course of the trial.16,27 The allocation ratio is
adapted to favour the allocation of future participants
into the intervention arms with more favourable interim
results.16,27 When a clinical trial investigation is done on
potentially life-saving therapies for deadly illnesses, RAR
can have a great appeal.28 For example, these type of
adaptations might be important for candidate thera
peutics to treat Ebola and COVID-19.29,30 Clinical trials
with RAR can potentially minimise the number of
participants assigned to control groups or other inferior
arms.31 However, there are risks for bias and inefficiencies
that might be introduced from having poorly planned
RAR. These designs for two-arm trials will have
lower statistical power than parallel-allocation designs
(eg, 1:1 allocation). In multiarm trials, RAR can improve
the probability of selecting the optimal treatment arm,
given that allocation to the control is adequately
maintained or even increased to match the allocation
ratio of the best-performing intervention arm.32 To
prevent bias that could arise due to poorly planned RAR
algorithms, extensive rounds of simulations should be
used to identify robust statistical constraints.8,16 It is also
important to recognise the challenges of implementing
RAR designs in resource-limited regions. For instance,
obtaining informed consent is already a difficult task in
global health research set in LMICs because many trials
in these settings involve vulnerable populations, such as
children. Given that these populations might have a
varied understanding of research intent or conduct, RAR
designs can raise complexities of obtaining consent from
participants.33

Interim analyses for stopping trials early
Adopting interim analyses that allow for individual
intervention arms or the trial itself to be stopped early
can improve the ethics and efficiency of clinical trials for
global health research. Interim evaluation in this context
would involve generating performance metrics on the
effectiveness and not just monitoring the trial progress
from the data that are collected. Stopping a trial early
could be due to superiority reasons, if the interim data
show that the intervention has sufficient evidence to
conclude that it is effective. For example, the HIV
trial of male circumcision in South Africa (ANRS 1265)
was ended early for superiority on the basis of an interim
analysis undertaken when 63% of the total planned
person-years had been observed.34 However, if the
interim data show that a given intervention has
inadequate benefit or sufficient activity, the trial can be
e693
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stopped early for futility. In a 2020 large-scale HIV vaccine
trial (HVTN 702) undertaken in South Africa, the
independent data monitoring committee reported no
benefits of the HIV vaccine when an interim analysis
showed a similar number of infections in the vaccinated
(n=129) and placebo (n=123) groups.35
Interim analyses for stopping trials early for either
superiority or futility can improve the core ethical
requirement of protecting research participants who
deserve special considerations, such as child populations.
Although it is commonly believed by researchers that
individuals will enrol in clinical trials under the belief that
their participation will help advance science,36 this is not
often the case. Participants might agree to enrol in a
clinical trial with a belief that they will gain personal
benefit in return for their participation, because their
participation could lead to access to clinical care and other
benefits that they would not normally have, which is
particularly likely in places where people have inadequate
health-care access or care is of poor quality (which are
contexts that are often targeted in global health research).37
Participants might be exposed to unknown risks given the
experimental nature of clinical trial research, particularly
in therapeutic interventional trials.37 Many clinical trials
involve marginalised and vulnerable populations that
might have a poor understanding of the research intent or
conduct.38–40 This was the case for three early trials of preexposure prophylaxis for the prevention of HIV in
Cambodia, Nigeria, and Cameroon, where ethical concerns
for minimal engagement in care post-trial were cited as the
primary reasons for stopping the studies early.41
There are several statistical methods for stopping trials
early. There are group sequential designs that allow for
trials to be stopped early if the test statistic, which
corresponds to a p value, exceeds a specified boundary
(a crucial value used to determine significance level) at a
preplanned interim analysis.42 To ensure that the overall
type I error rate does not exceed the desired α (eg, 5%), the
stopping boundaries are usually set more stringently at the
interim analyses. More stringent stopping boundaries are
used at interim analyses to account for multiplicity
(inflated errors due to multiple testing), to control for the
overall type I error rate.42 Stopping rules under the Bayesian
framework can also be implemented by prespecifying
decision rules that are specified in terms of probabilities.43,44
For instance, an adaptive Bayesian trial might allow for the
trial to be stopped early on the basis of superiority if the
estimated probability of success exceeds a threshold;
stopping trials early for futility can also be permitted if the
estimated probability of success falls below a specific
threshold.44 These thresholds for superiority and futility
are usually determined with statistical simulations that
yield desired operating characteristics.44

Other reasons for stopping trials early
In addition to superiority and futility reasons, there are
other reasons to end trials early. Regardless of design,
e694

careful attention is required to monitor adverse events
among participants during the trial, to allow for valid
assessment of harm. If an intervention is shown to be
harmful, early termination of the trial (or discontinuation
of the intervention arm in multiarm trials) could occur.
Measures to stop trials for adverse events are already
commonly implemented in global health research. A
trial might also end early if there are recruitment
challenges that can prevent the trial from finishing in a
timely manner. Recruitment is often a major challenge
for clinical trials undertaken in HICs.45,46 However,
LMICs might not have similar recruitment challenges
since there is often a higher burden of certain diseases.47,48
For low-prevalence diseases, such as neglected tropical
diseases, it is important to consider whether it is feasible
to recruit enough participants to answer the research
question reliably in the geographical setting.
There might be external reasons for ending trials early.
If new results from equivalent external studies become
available, there might no longer be clinical equipoise for
the intervention under study, raising ethical issues in
continuing the trial. This circumstance can impose a
serious ethical issue for participants randomised to the
control group, placebo, or outdated standard of care who
are undergoing clinical follow-up, as well as for future
participants who might be randomised to this less effective
(or even dangerous) control group.49,50 Additionally, with
other external developments (eg, alternative disease
control measures), the intervention being evaluated might
no longer be important.

Master protocol framework for global health
The current approach

In global health research, two-arm clinical trials that
compare one experimental intervention with the
standard of care or placebo (as the control group) are the
most often used study design (panel 1). Because there
are usually multiple intervention candidates in a given
research area, this can result in multiple trials being
undertaken independently, with redundant infra
structures created between different trials. These trials
also often have different, non-standardised operational
procedures; therefore, determining what the optimal
intervention for a given condition is becomes difficult
when the evidence comes from multiple heterogeneous
two-arm trials.51 Some of the current challenges in global
health research that arise from the preponderance of
two-arm trials might be overcome by imple
menting
multi
arm trials, particularly well designed platform
trials.52

Different types of master protocols
Master protocols are often categorised as platform trials,
basket trials, and umbrella trials (figure 1). Because
misunderstanding of master protocols is common, the
detailed descriptions of the key concept of platform
trials,53 as well as basket and umbrella trials,54 have been
www.thelancet.com/lancetgh Vol 9 May 2021
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described previously.14 In brief, a platform trial is a type
of clinical trial in which multiple interventions can
be evaluated simultaneously by use of a common
control group within a single master protocol that
shares the same infrastructure with standardised trial
procedures.14,15,53 In addition to multiple interventions
undergoing multiple interim evaluations simultaneously,
platform trials have the additional flexibilities of allowing
new experimental arms to be added and for the control
arm to be updated if the standard of care changes
throughout the trial.14,15,55–59 Platform trials can minimise
the number of participants allocated to the control group
by having a common control group. These trials allow for
multiple interventions to be evaluated in a perpetual
manner while collecting high-quality data that will enable
comparisons of the interventions that might be highly
relevant in informing new policy changes in global
health. For instance, the randomised evaluation of
COVID-19 therapy (RECOVERY) trial (ISRCTN50189673
and NCT04381936) is a large, ongoing, adaptive
platform trial based in the UK, and this trial has
produced important clinical trial evidence that has led to
improved inpatient management of patients with
COVID-19 worldwide (discussed further in the fourth
paper of this Series60).
Compared with platform trials, basket trials and
umbrella trials are designed to identify therapies that can
specifically affect disease targets (targeted therapies), to
improve the treatment of diseases.54 Basket trials evaluate
a targeted therapy for multiple diseases that share
common disease targets, whereas umbrella trials are
designed to evaluate multiple targeted therapies for a
single disease that is stratified into multiple subgroups.54
Because these disease targets are usually determined by
their genetic make-up, basket and umbrella designs have
predominantly been used in oncology research as
biomarker-guided trials.14,15 An example of a therapeutic
umbrella trial undertaken in LMICs for HIV is discussed
in panel 2.
Platform, basket, and umbrella trials are often
organised and planned with a modular protocol
structure, with the master protocol containing all generic
elements of the trial and intervention appendices that
are specific to each active intervention.7 With the use
of a modular format, adding a new intervention or
discontinuing a current intervention can become more
operationally seamless because the main study master
protocol does not need to be updated every time a new
intervention is added or discontinued in platform trials.
In basket and umbrella trials, common screening
mechanisms with standardised laboratory procedures
are used in different institutions and across different
geographical settings under one single master protocol.
This standardisation in operating procedures can help to
provide harmonisation of clinical trial research efforts
across different geo
graphical settings in the global
health field.
www.thelancet.com/lancetgh Vol 9 May 2021
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Figure 1: Master protocols: basket trials, umbrella trials, and platform trials
Master protocols refer to a single overarching protocol that has been developed to evaluate multiple hypotheses,
with the general goal of improving efficiency and establishing uniformity through standardisation of procedures in
the development and evaluation of interventions. Master protocols are often classified into basket trials, umbrella
trials, and platform trials. Basket trials refer to designs in which a targeted therapy is evaluated for multiple
diseases that share common molecular alterations or other risk factors. Umbrella trials evaluate multiple therapies
for a single disease that is stratified into different groups on the basis of molecular alterations or other risk factors.
However, platform trials have the flexibility of dropping ineffective interventions and adding new interventions
during the trial, while evaluating several interventions against a common control.

Benefits of a master protocol framework for
global health
Trials planned under the master protocol framework are
usually planned for the long term by forming a large trial
network across and throughout multiple institutions.13–15,62
Given that common standardised operating procedures
are established in multiple institutions through the
master protocol, the master protocol framework can allow
for a large amount of high-quality data to be collected.14,15
The research institutions can also more easily overcome
the issues of external changes that might occur during
the trial.63–65 Should a new therapeutic discovery be made
after a clinical trial begins, instead of launching a new
clinical trial, the new intervention can be added into the
trial and, if there are new changes in clinical practices,
these changes could be better adopted into the master
protocol and its standardised operating procedures.14,15
Insufficient or poorly organised infrastructure and low
human resource capacity for research are often cited
reasons as to why high-quality clinical trials are more
difficult to carry out in LMICs than HICs. However,
clinical trials in global health research are almost always
undertaken without any long-term consideration of
infrastructure and human resources in LMICs and the
likely substantial involvement of external actors in these

For more on the RECOVERY trial,
see https://www.recoverytrial.
net/
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Panel 2: HIV umbrella trial from South Africa (ACTG A5288)
To our knowledge, ACTG A5288 was one of the first umbrella
trials in low-income and middle-income countries (LMICs) to
evaluate new approaches for differentiated care in settings
where they have not been routinely used before.61 In this trial,
Grinsztejn and colleagues61 used the available knowledge on
antiretroviral therapy (ART) and real-time drug resistance
genotype monitoring to develop new third-line ART strategies
for people living with HIV at 19 urban sites in ten LMICs,
specifically in Africa (Kenya, Malawi, South Africa, Uganda, and
Zimbabwe), Latin America (Brazil, Haiti, and Peru), and
southeast Asia (India and Thailand). In this trial, patients who
had an inadequate response to second-line therapies and who
had varying resistance and susceptibility to different ARTs were
differentiated into four main cohorts (A, B, C, and D), with a
randomised mobile phone adherence support evaluation
embedded within the overall design. Participants who did not
show resistance to lopinavir (a second-line ART) were assigned
to cohort A, in which they continued to receive a second-line
ART. Participants resistant to lopinavir without resistance to
etravirine (a second-line ART) were assigned to cohort B.
Participants in cohort B without detectable hepatitis B surface
antigen were randomly assigned either to a best available
nucleoside reverse transcriptase inhibitor plus ritonavirboosted darunavir plus raltegravir as cohort B1, or ritonavirboosted darunavir plus raltegravir plus etravirine as cohort B2;
and those with detectable hepatitis B surface antigen were
assigned to cohort B3 to receive ritonavir-boosted darunavir
plus raltegravir and either tenofovir plus emtricitabine or
tenofovir plus lamivudine as an observational cohort.
Participants with resistance to etravirine and lopinavir or all
nucleoside reverse transcriptase inhibitors were assigned to

settings. Many regions in LMICs have not been given a
long-term opportunity to build and maintain ongoing
infrastructure that would also allow for local capacity
building to be leveraged at the same time. Instead,
historically when a clinical trial finishes, the infrastructure
usually disappears along with the research opportunities
for the local researchers. For many, this outcome results
in temporary unemployment and, sometimes, reticence
to participate in future clinical trials. For clinical trialists
initiating a new trial, recruiting experienced staff is
challenging and could delay the trial start date.
Given that master protocols are perpetual in nature, the
master protocol framework can help with the capacity
building and retention of trained staff under a large,
planned collaboration that recruits staff into secure roles
for a fixed but long period, in which multiple questions
can be addressed over time in one single trial. If the longterm goal is to build the capacity for clinical research
in LMICs, then planning for long-term employment is
necessary to offer professional development oppor
tunities. Undertaking one large trial under the master
protocol framework can also save on resources that are
e696

cohort C to receive ritonavir-boosted darunavir plus raltegravir
plus tenofovir plus lamivudine, and those who were ineligible
for cohorts A, B, and C were assigned to cohort D to receive the
best available nucleoside reverse transcriptase inhibitors plus
ritonavir-boosted darunavir plus raltegravir.
Between January, 2013, and September, 2015, 545 participants
were enrolled into this umbrella trial. 287 (53%) of
545 participants were assigned to cohort A; 154 (27%) of
545 participants were randomly assigned to either cohort B1
(74 [14%] of 545 participants) or cohort B2 (72 [13%] of
545 participants), and 8 (1%) of 545 participants were assigned
to cohort B3. 70 (13%) of 545 participants were assigned to
cohort C and 34 (6%) of 545 participants were assigned to
cohort D. In this trial, 424 (78%) of the 545 participants who
did not respond to second-line ART had at least one mutation
to nucleoside reverse transcriptase inhibitors, non-nucleoside
reverse transcriptase inhibitors, or protease inhibitors.
Only 146 (27%) of the 545 participants had thymidine analogue
mutations known to cause a reduction of ART activity.
Understanding each patient’s treatment history and their
genotype is paramount to define future regimens. This
understanding becomes complicated in non-research settings
because of low coverage of and access to viral load monitoring
and low capacity for real-time genotyping in most LMICs. Given
the need to offer regimens based on treatment history, umbrella
trials allow for targeted strategies that allow clinicians to interpret
signals about whether more or less favourable outcomes occur in
the targeted populations. The assembled infrastructure and
capacity to carry out real-time genotyping in LMICs can help to
improve the clinical services in these resource-limited settings.

required in setting up multiple independent clinical
trials, and savings should be diverted to the health-care
professionals based in the sites of investigation, and this
framework can identify and address gaps in the research
infrastructure that are common barriers to undertaking
clinical trials in LMICs.
This cost-saving, which is both a feature of direct and
indirect benefits, can instead be diverted to building
human resource capacity and research infrastructure in
LMICs. In addition to staff training and capacity building,
acquisition costs for specialised equipment can be
consolidated. For example, the WHO Stepwise Laboratory
Quality Improvement Process Towards Accreditation in
the African region (also known as SLIPTA) initiative66 has
specifically mentioned the need for experts and centres
of excellence in LMICs to improve disease prevention
and control. The systemic longevity and specialised
methodologies intrinsic to many master protocols should
be well aligned with pre-existing efforts, such as
the African Strategies for Advancing Pathology,67 to build
on the unique opportunities that the master protocol
framework can provide.
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Perpetual clinical trials allow for the long-term
involvement of the community in the planning of future
clinical trials. For these perpetual clinical trials to be
meaningful, the scope of research should be driven by
local researchers, to correctly target areas that are key
priorities in the location of the trial. Key community
members (eg, trusted community health-care workers)
represent important knowledge translation agents of
the trial conduct and study findings for the affected
populations. Long-term trust can encourage participant
enrolment, retention, and involvement of the dissemi
nation of study findings. Mechanisms to engage with local
institutions and ethics review boards can be implemented
to enable dialogue around changes in the conduct and
evaluation of the trials, to ensure ethical conduct.

General framework for more efficient trials in
global health
There are several important questions for clinical trial
research that deserve consideration during the planning
stage (panel 3). These questions can serve as a general
framework to improve the efficiency of trials, in global
health research and beyond.
In the planning stage, it is important to identify areas
of uncertainty and anticipate different scenarios with
possible trajectories that might be observed during
the trial. There should be extensive discussions with
clinical experts based in the area that the trial will be set,
and with key opinion leaders with geographical and
sociocultural familiarity with that area.
There should be early discussions to identify admin
istrative structures and logistics of data collection,
monitoring, and implementing adaptations that could
potentially limit the feasibility of undertaking an adaptive
clinical trial.68 Administrative and operational logistic
factors (eg, expected recruitment time and time to
implement adaptations) should be discussed with local
stakeholders and clinical staff who will be responsible for
managing the day-to-day operations of the clinical trial. If
the outcome for the prespecified adaption takes a long
time to measure in comparison with the recruitment
time, adaptive trial designs might not be feasible because
the planned recruitment might be completed before a
sufficient number of clinical outcomes can be observed.68
Whether they are adaptive or not, clinical trial
simulations can be used for any trial design and any areas
within the global health field.9 These tools allow trial
investigators to explore, compare, and better understand
the fragility of assumptions, to produce the most optimal
trial design for a given research question.69–71 Simulations
allow for an assessment of different designs, including
fixed trial designs, for their operating characteristics
(eg, expected sample size, type I error rates, and statistical
power) under several scenarios.71 Simulations can also be
used to assess other metrics (eg, estimated number of
interventions and placebo doses required), to improve
resource and operational planning of the trial.71,72
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Panel 3: General considerations for efficient clinical trial
research
1 Does the trial ask a question on which there is genuine
uncertainty and is the trial design appropriate for
answering the question?
2 Does the trial use a control intervention that reflects
routine care?
3 Is the trial evaluating interventions that are feasible for
use in the setting?
4 Does the trial enrol the population that is most likely to
benefit from the results of the trial (show treatment effect)?
5 Have the investigators examined all important
uncertainties in the planning stage (eg, examined
different control event rates to see how they affect the
statistical power)?
6 Have the investigators planned for areas of anticipated
regret and other unanticipated changes (eg, planned and
implemented a sample size re-assessment during the trial
to avoid anticipated regret)?
7 Have the investigators planned for continuity of the
treatment or approach to the trial?

Good simulation practices that have been described for
pharmaceutical development can be extended to global
health research.71 Clinical trialists and clinicians involved
in the trial do not need to understand every aspect of the
statistical assumptions and underlying technical details to
partake in group discussions during the planning stage.
Because simulations are an iterative process, the initial
group discussion on simulation can start with simple
simulations to engage the local clinical experts and key
opinion leaders and help them to become more familiar
with interpreting trial simulation results.8 Then, in
subsequent rounds of simulations, more comprehensive
simulations on other more complicated scenarios can be
shared for feedback.8
Funders could promote the use of simulations and
thus more efficient trial planning for global health
research if the funders place a requirement for
simulations to be included as part of the application
process instead of just simple sample size calculations.
For instance, when the US Food and Drug Administration
recognised the value of simulations and emphasised
their use in trial planning, this recognition catalysed the
use of simulations in the pharmaceutical industry.7,73
Across different LMICs, promotion of simulations will
most likely require collaboration and communications
between different donors, regulatory authorities, and
global health organisations.

Challenges with adaptive trial designs and
master protocols
Methodological and operational complexity

Adaptive trial designs and master protocols can be
inherently more methodologically and operationally
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Series

Total sample size
Control group sample size

Scenario 1: multiple two-arm trials

RCT 2

Control 2
Intervention 2

RCT 3

Control 3
Intervention 3

RCT 4

Control 4
Intervention 4

Scenario 2: single multiarm trial

6000

Sample size

RCT 1

Control 1
Intervention 1

Multiarm
trial

Control 1
Intervention 1
Intervention 2
Intervention 3
Intervention 4

4000

37·5% average
saving

14·3% average
saving

5200
4550
3900

2000

3250
2600

0

1950
650

1300

Scenario 1 Scenario 2 Scenario 3 Scenario 4

RCT 1

Scenario 3: clinical trials under non-master protocol
Control 1
Intervention 1
Intervention 2
Total cost
Direct cost

RCT 2

Control 2
Intervention 3
8·0

Cost (millions US$)

RCT 3

Control 3
Intervention 4

Scenario 4: single platform trial
Platform trial

Common control
Intervention 1
Intervention 2

6·0

Intervention 4
1

2

3

4
Year

5

6

7

8

12·7% average
saving

5·97
5·10
4·11

4·45

3.36

2·0

Intervention 3
0

.

Funding challenges

31·2% average
saving

4·0

0

4·50

3·36

3·97

3·63

Scenario 1 Scenario 2 Scenario 3 Scenario 4

Figure 2: Comparison of two-arm, multiarm, and platform trial approaches on sample size and cost
For all scenarios, we assumed that there would be four experimental interventions that will be evaluated.
We considered fixed trial designs, in which all clinical trials would end their recruitment in each arm when the
target sample size of 650 patients was met. We assumed that a dichotomous outcome will be used as the primary
outcome, with pairwise comparison with the control being planned as the primary analysis. The sample size per
arm required to achieve 80% statistical power and 5% type I error rate was calculated by assuming an event rate
of 40%, an effect size of 20% relative risk reduction, and 10% loss to follow-up rate. Because there are four
independent trials being conducted in scenario 1, we defined the maximum total cost (direct and indirect cost) to
be US$6·0 million assuming that each of the research grants will be for the amount of US$1·5 million. Detailed
explanations are provided in the appendix (pp 2–5). RCT=randomised clinical trial.

complex than conventional fixed trial designs. Incorrectly
planned or executed adaptive trial designs can introduce
statistical and operational biases.74 Although more time
and resources will be dedicated to the planning stage,
this is a far preferable alternative than the current norm
of insufficient trial planning practices that occur too
frequently in all areas of clinical trial research, including
in the global health field. Consolidating resources and
collaborations across a wider network of researchers and
institutions from different geographical regions will be
important for global health research. Instead of creating
different control groups, having a common control group
can be more statistically efficient. Geographical variability
could also be better represented by master protocols
because standardised operating procedures will be
implemented across different institutions, to record the
data into a common centralised database.
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Undoubtedly, implementing master protocols will have
considerable logistic and operational challenges. For
instance, there will be different standards of care across
different countries and geographical settings. However,
this challenge is not new: many multicentre, multi
national clinical trials have successfully overcome similar
problems. The rationale for adding a new intervention
and the mechanisms should be discussed early with the
ethics and regulatory bodies, to ensure that new
interventions can be added in a timely manner.
We hope that these challenges will not be used as an
argument to deter from the use of these innovative
trial design approaches in global health research. Many
of these operational challenges and barriers can be
minimised in the planning stage by researchers based in
the trial setting. Multidisciplinary collaborative efforts
can easily overcome the planning challenges.
In global health research, clinical trial funding predominantly relies on grants from government funding
agencies and non-profit organisations, and the demand
for funding by far exceeds supply. The funding value from
the US National Institutes of Health, for example, is
usually fixed for all applications that might vary in scope. In
practice, clinical trial sample size and trial duration
are limited due to budget constraints. Optimistic
assumptions about the treat
ment effects and baseline
event rates are picked to justify the sample size that is
suitable for the budget, to stay competitive during the
application stage. For illustrative purposes, sample size
and cost-savings are shown in figure 2. Master protocols
and adaptive clinical trials might require more resources
than the budget that is typically allowed by the funder.
Under the current funding scheme, the feasibility of
undertaking these larger trials is limited even though
such trials can improve efficiency and introduce other
long-term benefits to staff who are based at the trial
location and to local infrastructure. In clinical trials that
are sponsored by the pharmaceutical industry, if the trial
stops early for either futility or superiority, the remaining
budget goes back into the research and development
budget to finance other clinical trials. In publicly funded
clinical trials for which securing funding is already so
competitive, it is difficult to imagine academic research
groups returning their funding, or the academic centres
in HICs handing back their overheads to funders to be
used to fund research centres in LMICs. For the global
health funding agencies, it is important to consider
funding long-term projects that can harbour data-driven
techniques, to gain efficiencies as long-term investments
that can harmonise and improve quality of clinical trial
research while building research infrastructure and
improving professional development opportunities in
LMICs. Funding of long-term projects could be improved
by better coordination between funding agencies, which
can fund projects in prioritised clinical areas that align
www.thelancet.com/lancetgh Vol 9 May 2021
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with the changing disease burden in LMICs. This
approach will require a conceptual change to mandate
the funding to be allocated in ways that would catalyse
infrastructure and professional development in LMICs.

Conclusion
Adaptive trial designs and master protocols have
predominantly been used for research in HICs so far.
Increasing awareness and understanding of these
concepts will be crucial for global health researchers and
their funders, to improve the efficiency and ethics of
global health trials. Master protocol frameworks can help
to improve the quality of clinical trial research by
harmonising research efforts across different LMICs,
and they could potentially be used to improve local
infrastructure and offer more quality professional
development opportunities at the trial setting.
Contributors
JJHP and EJM conceptualised the paper. JJHP, NF, ZAB, KT, MES, and
EJM acquired and analysed the data. All authors interpreted the data.
JJHP drafted the paper. All authors critically revised the paper for
important intellectual content. EJM obtained the funding, and JJHP and
EJM provided administrative, technical, and material support and
supervised the study.
Declaration of interests
DX reports grants from AstraZeneca, grants from Boehringer
Ingelheim, grants from Bristol Myers Squibb, grants from Coca-Cola
India, speaker’s fees from Eli Lilly, speaker’s fees from the Indian
Council of Medical Research, grants from Pfizer, speaker’s fees from
Sanofi, grants from the UK Medical Research Council, and grants from
the Wellcome Trust, outside of the submitted work. All other authors
declare no competing interests.
Acknowledgments
This Series was supported by the Bill & Melinda Gates Foundation. No
authors received funding, and all authors volunteered their time. The
funding source had no role in the design and implementation of the
study; collection, management, analysis, and interpretation of the data;
preparation, review, or approval of the paper; and decision to submit the
paper for publication. The funding provided by the Gates Foundation
was used for administrative support to coordinate submission efforts.
The contents of the paper are the sole responsibility of the authors and
might not necessarily represent the official views of the Gates
Foundation or other agencies that might have supported the primary
data studies used in the present study. The corresponding author (EJM)
had the final responsibility for the decision to submit for publication.
References
1
Park JJH, Fang ML, Harari O, et al. Association of early interventions
with birth outcomes and child linear growth in low-income and
middle-income countries: Bayesian network meta-analyses of
randomized clinical trials. JAMA Netw Open 2019; 2: e197871.
2
van Eijk AM, Larsen DA, Kayentao K, et al. Effect of
Plasmodium falciparum sulfadoxine-pyrimethamine resistance on
the effectiveness of intermittent preventive therapy for malaria in
pregnancy in Africa: a systematic review and meta-analysis.
Lancet Infect Dis 2019; 19: 546–56.
3
Esu EB, Oringanje C, Meremikwu MM. Intermittent preventive
treatment for malaria in infants. Cochrane Database Syst Rev 2019;
12: CD011525.
4
González R, Pons-Duran C, Piqueras M, Aponte JJ, Ter Kuile FO,
Menéndez C. Mefloquine for preventing malaria in pregnant
women. Cochrane Database Syst Rev 2018; 11: CD011444.
5
Bauer P, Bretz F, Dragalin V, König F, Wassmer G. Twenty-five years
of confirmatory adaptive designs: opportunities and pitfalls.
Stat Med 2016; 35: 325–47.
6
Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med
2016; 375: 65–74.

www.thelancet.com/lancetgh Vol 9 May 2021

7

8
9
10
11
12
13
14
15
16
17
18
19
20

21

22
23

24
25
26
27
28

29
30
31

US Food and Drug Administration. Adaptive designs for medical
device clinical studies guidance for industry and Food and Drug
Administration staff. 2016. https://www.fda.gov/media/92671/
download (accessed Dec 8, 2020).
Thorlund K, Haggstrom J, Park JJ, Mills EJ. Key design
considerations for adaptive clinical trials: a primer for clinicians.
BMJ 2018; 360: k698.
Park JJH, Grais RF, Taljaard M, et al. Urgently seeking efficiency
and sustainability of clinical trials in global health.
Lancet Glob Health 2021; 9: e681–90.
Woodcock J, LaVange LM. Master protocols to study multiple
therapies, multiple diseases, or both. N Engl J Med 2017; 377: 62–70.
Redman MW, Allegra CJ. The master protocol concept. Semin Oncol
2015; 42: 724–30.
Renfro LA, Sargent DJ. Statistical controversies in clinical research:
basket trials, umbrella trials, and other master protocols: a review
and examples. Ann Oncol 2017; 28: 34–43.
Hirakawa A, Asano J, Sato H, Teramukai S. Master protocol trials in
oncology: review and new trial designs. Contemp Clin Trials Commun
2018; 12: 1–8.
Siden EG, Park JJ, Zoratti MJ, et al. Reporting of master protocols
towards a standardized approach: a systematic review.
Contemp Clin Trials Commun 2019; 15: 100406.
Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket
trials, umbrella trials, and platform trials: a landscape analysis of
master protocols. Trials 2019; 20: 572.
Park JJ, Thorlund K, Mills EJ. Critical concepts in adaptive clinical
trials. Clin Epidemiol 2018; 10: 343–51.
Legocki LJ, Meurer WJ, Frederiksen S, et al. Clinical trialist
perspectives on the ethics of adaptive clinical trials: a mixedmethods analysis. BMC Med Ethics 2015; 16: 27.
Chow SC, Corey R. Benefits, challenges and obstacles of adaptive
clinical trial designs. Orphanet J Rare Dis 2011; 6: 79.
Herson J. Data and safety monitoring committees in clinical trials.
Boca Raton, Florida: CRC Press, 2016.
DAMOCLES Study Group, NHS Health Technology Assessment
Programme. A proposed charter for clinical trial data monitoring
committees: helping them to do their job well. Lancet 2005;
365: 711–22.
Clinical Trials Transformation Initiative. CTTI recommendations:
data monitoring committees. 2016. https://www.ctti-clinicaltrials.
org/files/recommendations/dmc-recommendations.pdf (accessed
Dec 8, 2020).
Bauer P, Koenig F. The reassessment of trial perspectives from
interim data—a critical view. Stat Med 2006; 25: 23–36.
European Medicines Agency. Statistical principals for clinical trials:
ICH harmonised tripartite guideline. 1998. https://www.ema.
europa.eu/en/documents/scientific-guideline/ich-e-9-statisticalprinciples-clinical-trials-step-5_en.pdf (accessed Dec 8, 2020).
Cuffe RL, Lawrence D, Stone A, Vandemeulebroecke M. When is a
seamless study desirable? Case studies from different
pharmaceutical sponsors. Pharm Stat 2014; 13: 229–37.
Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine
against infection and intraepithelial neoplasia in women.
N Engl J Med 2015; 372: 711–23.
Chen YH, Gesser R, Luxembourg A. A seamless phase IIB/III
adaptive outcome trial: design rationale and implementation
challenges. Clin Trials 2015; 12: 84–90.
Biswas A, Bhattacharya R. Response-adaptive designs for
continuous treatment responses in phase III clinical trials: a review.
Stat Methods Med Res 2016; 25: 81–100.
Berry SM, Petzold EA, Dull P, et al. A response adaptive
randomization platform trial for efficient evaluation of Ebola virus
treatments: a model for pandemic response. Clin Trials 2016;
13: 22–30.
Nakkazi E. Randomised controlled trial begins for Ebola therapeutics.
Lancet 2018; 392: 2338.
Drugs for Neglected Diseases initiative. ANTICOV. 2020.
https://dndi.org/research-development/portfolio/anticov (accessed
Nov 25, 2020).
Meurer WJ, Lewis RJ, Berry DA. Adaptive clinical trials: a partial
remedy for the therapeutic misconception? JAMA 2012;
307: 2377–78.

e699

Series

32
33
34

35
36
37
38

39
40

41
42
43
44
45
46
47
48

49
50

51
52
53
54
55

e700

Viele K, Broglio K, McGlothlin A, Saville BR. Comparison of
methods for control allocation in multiple arm studies using
response adaptive randomization. Clin Trials 2020; 17: 52–60.
Sim J. Outcome-adaptive randomization in clinical trials: issues of
participant welfare and autonomy. Theor Med Bioeth 2019; 40: 83–101.
Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R,
Puren A. Randomized, controlled intervention trial of male
circumcision for reduction of HIV infection risk: the ANRS 1265
Trial. PLoS Med 2005; 2: e298.
Cohen J. Another HIV vaccine strategy fails in large-scale
study. 2020. https://www.sciencemag.org/news/2020/02/anotherhiv-vaccine-strategy-fails-large-scale-study (accessed Dec 8, 2020).
Zarin DA, Goodman SN, Kimmelman J. Harms from uninformative
clinical trials. JAMA 2019; 322: 813.
Lema VM. Therapeutic misconception and clinical trials in
sub-Saharan Africa: a review. East Afr Med J 2009; 86: 291–99.
Scott M, Watermeyer J, Nolle S, Penn C. Perceived challenges in the
informed consent process: mismatches between enrollers and
researchers at a South African clinical research site.
Developing World Bioeth 2019; 19: 206–14.
Carman AS, Sautter C, Anyanwu JN, et al. Perceived benefits and
risks of participation in a clinical trial for Ugandan children with
sickle cell anemia. Pediatr Blood Cancer 2020; 67: e27830.
Nalubega S, Evans C. Participant views and experiences of
participating in HIV research in sub-Saharan Africa: a qualitative
systematic review. JBI Database Syst Rev Implement Reports 2015;
13: 330–420.
Mills EJ, Singh S, Singh JA, Orbinski JJ, Warren M, Upshur RE.
Designing research in vulnerable populations: lessons from HIV
prevention trials that stopped early. BMJ 2005; 331: 1403–06.
Jennison C, Turnbull BW. Group sequential methods with
applications to clinical trials. New York, NY: Chapman and Hall/
CRC, 1999.
Berry DA. Bayesian clinical trials. Nat Rev Drug Discov 2006; 5: 27–36.
Thorlund K, Haggstrom J, Park JJ, Mills EJ. Key design
considerations for adaptive clinical trials: a primer for clinicians.
BMJ 2018; 360: k698.
Fogel DB. Factors associated with clinical trials that fail and
opportunities for improving the likelihood of success: a review.
Contemp Clin Trials Commun 2018; 11: 156–64.
Bower P, Wallace P, Ward E, et al. Improving recruitment to health
research in primary care. Fam Pract 2009; 26: 391–97.
Devasenapathy N, Singh K, Prabhakaran D. Conduct of clinical
trials in developing countries: a perspective. Curr Opin Cardiol 2009;
24: 295–300.
Mbuagbaw L, Thabane L, Ongolo-Zogo P, Lang T. The challenges
and opportunities of conducting a clinical trial in a low resource
setting: the case of the Cameroon mobile phone SMS (CAMPS)
trial, an investigator initiated trial. Trials 2011; 12: 145.
Zannad F, Gattis Stough W, McMurray JJ, et al. When to stop a
clinical trial early for benefit: lessons learned and future
approaches. Circ Heart Fail 2012; 5: 294–302.
Kent DM, Mwamburi DM, Bennish ML, Kupelnick B, Ioannidis JP.
Clinical trials in sub-Saharan Africa and established standards of
care: a systematic review of HIV, tuberculosis, and malaria trials.
JAMA 2004; 292: 237–42.
Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and
network meta-analysis. BMJ 2013; 346: f2914.
Parmar MK, Carpenter J, Sydes MR. More multiarm randomised
trials of superiority are needed. Lancet 2014; 384: 283–84.
Park JJH, Harari O, Dron L, Lester RT, Thorlund K, Mills EJ.
An overview of platform trials with a checklist for clinical readers.
J Clin Epidemiol 2020; 125: 1–8.
Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of
precision oncology basket and umbrella trials for clinicians.
CA Cancer J Clin 2020; 70: 125–37.
Sydes MR, Parmar MK, Mason MD, et al. Flexible trial design in
practice—stopping arms for lack-of-benefit and adding research
arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized
controlled trial. Trials 2012; 13: 168.

56
57
58

59

60
61
62
63
64
65
66

67

68
69
70
71
72
73

74

Barthel FM, Parmar MK, Royston P. How do multi-stage, multi-arm
trials compare to the traditional two-arm parallel group design—
a reanalysis of 4 trials. Trials 2009; 10: 21.
Sydes MR, Parmar MK, James ND, et al. Issues in applying multiarm multi-stage methodology to a clinical trial in prostate cancer:
the MRC STAMPEDE trial. Trials 2009; 10: 39.
James ND, Sydes MR, Clarke NW, et al. STAMPEDE: systemic
therapy for advancing or metastatic prostate cancer—a multi-arm
multi-stage randomised controlled trial. Clin Oncol (R Coll Radiol)
2008; 20: 577–81.
Parmar MK, Sydes MR, Cafferty FH, et al. Testing many treatments
within a single protocol over 10 years at MRC Clinical Trials Unit at
UCL: multi-arm, multi-stage platform, umbrella and basket
protocols. Clin Trials 2017; 14: 451–61.
Park JJH, Mogg R, Smith GE, et al. How COVID-19 has
fundamentally changed clinical research in global health.
Lancet Glob Health 2021; 9: e711–20.
Grinsztejn B, Hughes MD, Ritz J, et al. Third-line antiretroviral
therapy in low-income and middle-income countries (ACTG A5288):
a prospective strategy study. Lancet HIV 2019; 6: e588–600.
Woodcock J, LaVange LM. Master protocols to study multiple
therapies, multiple diseases, or both. N Engl J Med 2017;
377: 62–70.
Ventz S, Alexander BM, Parmigiani G, Gelber RD, Trippa L.
Designing clinical trials that accept new arms: an example in
metastatic breast cancer. J Clin Oncol 2017; 35: 3160–68.
Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision
of the future. Clin Trials 2016; 13: 358–66.
Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient
strategy for evaluating multiple treatments. JAMA 2015;
313: 1619–20.
WHO. Stepwise Laboratory Quality Improvement Process Towards
Accreditation (SLIPTA) checklist version 2: 2015 for clinical and
public health laboratories. 2015. https://apps.who.int/iris/
handle/10665/204423 (accessed Dec 8, 2020).
African Strategies for Advancing Pathology Group Members.
Quality pathology and laboratory diagnostic services are key to
improving global health outcomes: improving global health
outcomes is not possible without accurate disease diagnosis.
Am J Clin Pathol 2015; 143: 325–28.
Wason JMS, Brocklehurst P, Yap C. When to keep it simple—
adaptive designs are not always useful. BMC Med 2019; 17: 152.
Westfall PH, Tsai K, Ogenstad S, Tomoiaga A, Moseley S, Lu Y.
Clinical trials simulation: a statistical approach. J Biopharm Stat
2008; 18: 611–30.
Hummel J, Wang S, Kirkpatrick J. Using simulation to optimize
adaptive trial designs: applications in learning and confirmatory
phase trials. Clin Investig (Lond) 2015; 5: 401–13.
Mayer C, Perevozskaya I, Leonov S, et al. Simulation practices for
adaptive trial designs in drug and device development.
Stat Biopharm Res 2019; 11: 325–35.
Gaydos B, Anderson KM, Berry D, et al. Good practices for adaptive
clinical trials in pharmaceutical product development. Drug Inf J
2009; 43: 539–56.
US Food and Drug Administration. Adaptive designs for drugs and
biologics guidance for industry. 2019. https://www.fda.gov/
regulatory-information/search-fda-guidance-documents/adaptivedesign-clinical-trials-drugs-and-biologics-guidance-industry
(accessed Dec 8, 2020).
Detry MA, Lewis RJ, Broglio KR, Connor JT, Berry SM, Berry DA.
Standards for the design, conduct, and evaluation of adaptive
randomized clinical trials. 2012. https://www.pcori.org/sites/
default/files/Standards-for-the-Design-Conduct-and-Evaluation-ofAdaptive-Randomized-Clinical-Trials1.pdf (accessed Dec 8, 2020).

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an
Open Access article under the CC BY 4.0 license.

www.thelancet.com/lancetgh Vol 9 May 2021

